The article describes a study examining placebo effects associated with the administration of a hypothetical ergogenic aid in sport. Forty-two team-sport athletes were randomly assigned to 2 groups. All subjects completed 3 × 30-m baseline sprint trials after which they were administered what was described to them as an ergogenic aid but was in fact 200 mg of cornstarch in a gelatin capsule. Group 1 was provided with positive information about the likely effects on performance of the substance, whereas Group 2 was provided with negative information about the same substance. The sprint protocol was repeated 20 min later. Although for Group 1 mean speed did not differ significantly between baseline and experimental trials, a significant linear trend of greater speed with successive experimental trials suggested that positive belief exerted a positive effect on performance (P < 0.01). Group 2 ran 1.57% slower than at baseline (P < 0.01, 95% confidence intervals 0.32-2.82%), suggesting that negative belief exerted a negative effect on performance. Collectively, data suggest that subjects' belief in the efficacy or otherwise of a placebo treatment might significantly influence findings in experimental research.
The use of nutritional ergogenic aids is prevalent in sports. There is, however, debate regarding the efficacy of many of these substances, and several are associated with documented health risks. Research that seeks to evaluate the efficacy of any potentially ergogenic substance is thus of significance to both the performance and the health of athletes. Furthermore, given the widespread use of substances such as caffeine, creatine monohydrate, and anabolic steroids among recreational exercisers and adolescents (15) , such research is arguably significant to society generally. In order to ensure the validity and reliability of findings in this area of research, methodologies that can reliably identify a direct ergogenic effect on performance and distinguish this from any indirect effects should be employed. Methodological recommendations to this end often focus on controlling metabolic factors such as habituation, training load, and dietary status, and control of psychological factors such as the placebo effect-a change arising from a subject's perceptions about the likely outcome from receiving a treatment-is achieved through use of the placebo-control condition (10, 13) .
It is reasonable to suggest that the widespread use of the placebo-control condition in research demonstrates that most sports scientists acknowledge that performance can be influenced by the placebo effect. In research settings, however, it is typically assumed that the placebo effect is somehow static or standardized, and little has been done to measure the magnitude, direction, or variability of the effect. In sport, only 4 published articles have explicitly addressed the phenomenon (2, 7, 8, 14) . These studies demonstrated that subjects experienced placebo effects in response to the belief that they had ingested substances such as anabolic steroids, caffeine, and carbohydrate solution. These findings, alongside anecdotal and qualitative evidence (e.g., 5, 6, 17) , not only suggest that the placebo effect is a factor in sports performance but also hint at some less widely acknowledged aspects of the effect, for example, the possibility that negative beliefs might negatively affect performance (7) . Given that effect sizes are often estimated on the assumption that any placebo effect is positive in comparison with true baseline performance, the occurrence of such a negative placebo (or "nocebo") effect in research would have implications for the validity of the findings.
In the study reported here, we sought to explore the suggestion that a placebo effect might exert a negative influence on performance. The study had full approval of our institutional ethics committee and adhered to the American Psychological Association's (1) ethical guidelines for the conduct of such research.
Method
Using a mixed factorial design, the present study tested 2 hypotheses: first, that after ingestion of a placebo nutritional ergogenic aid, subjects who have positive beliefs about the substance will perform to a higher level than subjects who have negative beliefs about the same substance and, second, that subjects who have negative beliefs about an intervention will perform at a level below baseline in experimental conditions.
Subjects
Forty-two team-sport athletes (mean age 19.6 ± 2.9 y) from sports including basketball, field hockey, netball, rugby football, and soccer agreed to participate in the study. After a briefing session, subjects were randomly allocated to 1 of 2 groups: Group 1 (positive belief) and Group 2 (negative belief). Both groups were informed that they would be completing a repeat-sprint protocol in 2 conditions, baseline and experimental. They were further informed that before the experimental condition they would be administered an ergogenic aid hypothesized to have an effect on their performance. (Participants who reported any allergies, prior adverse responses to medication, or current or recent health problems requiring medication were excluded from the study to minimize the possibility of adverse responses to the belief that an active treatment had been received.)
Measure
A 30-m repeat-sprint protocol was selected as being a task common to a wide variety of team sports. Previous data collected at our institution using the same subjects suggest that the test has good reliability, with a coefficient of variation of 2.7% (data from one 30-m sprint trial were collected once per week in the 4 wk before the present study as part of a reliability study).
Procedure
To minimize the potential for experimenter effects, a highly experienced researcher not associated with the original research project was responsible for managing the data-collection process. To control for biological and meteorological variation, all data were collected on the same day. To maintain the experimental blind, both experimental groups were isolated from one other after the initial briefing session. All subjects underwent a standardized 20-min warm-up before all data collection. They then performed three 30-m sprints (baseline Trials 1-3) with 2 min recovery between. The starting position for all sprints was standardized from a 1-m standing start, and time was recorded to the nearest 0.01 s using light timing gates. Participants were then administered the "ergogenic aid," a red and white gelatin capsule containing 200 mg of cornstarch. Each group was, however, provided a different description of the contents of the capsule: The positive-belief group was informed that the substance had been found to enhance both repeat-sprint and endurance performance in team-sport players, whereas the negative-belief group was informed that the substance had been found to enhance endurance performance while having a negative impact on repeat-sprint performance. Twenty minutes after the intervention-a period during which a standardized low-intensity exercise regimen was maintained-subjects undertook experimental Trials 4-6 in a manner identical to that of the baseline trials. After completing these and after a cool-down, and in accordance with APA guidelines (1), subjects were taken for a debriefing session during which the true nature of the study was disclosed and postexperiment questionnaires were completed.
Results
A plot of mean times for each condition by group is presented in Figure 1 . From this figure it can be seen that the speed of both groups diminished progressively in successive baseline trials. For the negative-belief group this trend toward reduced speed continued into experimental trials. This trend was not, however, observed in the positive-belief group, whose mean speed increased in successive experimental trials.
Differences in time (in seconds) and 95% confidence intervals for both groups are presented in Tables 1 and 2 . ANOVA indicated that subjects in the positivebelief group ran significantly more slowly in Trials 3 and 4 than in Trials 1 and 6 (mean speed for Trials 1 and 6 were identical), and subjects in the negative-belief group ran significantly more slowly in Trials 5 and 6 than in Trial 1 (and in the case of Trial 6, than in Trial 2). Whereas no change in mean speed from baseline to experimental trials was evident for the positive-belief group (P = 0.96), data for the negative-belief group indicated that they ran on average .08 s (1.7%) more slowly in experimental trials (P = 0.01). Mean delta score (baseline to experimental) for the positive-belief group was 0.00 (± 0.09), and that for the negative-belief group was 0.09 (± 0.10). Differences in delta scores between groups were also significant (P = 0.01), suggesting that negative beliefs about the intervention had a significant negative impact on subjects' subsequent performance. ANOVA also indicated a significant linear trend of greater running speed with each successive experimental trial (P < 0.01) in the positive-belief group, suggesting that positive belief exerted a significant positive impact on performance. A significant interaction of belief on time was evident (P < 0.01). Collectively, results suggest that both positive and negative beliefs about the substance were associated with placebo effects of different polarity that differentially and significantly affected performance.
Previous research has suggested that there might be a degree of interindividual variability in the placebo response (7, 10) . Atkinson and Nevill (3) suggest that researchers should specify how reliability analysis influences the interpretation of individual responses and report that the International Standards Organization (ISO) advocates using the 95% limits of agreement (±1.96 × coefficient of variation) to indicate the limits represented by measurement error. Atkinson and Nevill suggest that if changes are outside these limits they are likely to be real. It was evident that in the positive-belief group 26% of individual performances fell outside individual 95% limits of agreement and that only 50% of these (i.e., 13% of the group) were faster than the upper limit. It was observed, however, that all performances below the lower limit for the positive-belief group were in the first experimental trial (i.e., Trial 4), with no performances slower than the lower limit being observed in either Trial 5 or Trial 6. In the negative-belief group, 33% of performances fell outside the limits of agreement, and all of these were slower than the lower limit. Furthermore, 50% of these slower performances were observed in Trial 6. Data from a post hoc questionnaire indicated that 95% of subjects believed that ergogenic aids such as caffeine could enhance sports performance. Fifty percent of subjects indicated that before the trials they had expected the capsule to affect their sprint performance. Of subjects in the negative-belief group, however, 64% were unsure as to whether the experimental manipulation had had an effect on their performance, and this figure increased to 76% in the positive-belief group. None of the positive-belief group and only 8% of the negative-belief group reported any signs or symptoms attributable to the capsules. No pattern of relationships between questionnaire responses and response to the experimental manipulation was discernible.
Discussion
Consistent with previous experimental research in sport (2, 7, 8, 14) , the study reported here demonstrates that placebo effects in sports performance are likely to be observed when subjects believe that they have ingested an ergogenic substance. Whereas previous research has demonstrated that variability in observed placebo effects might be a function of subjects' beliefs about whether or not they have ingested that substance, present findings suggest that such variability is also a function of subjects' beliefs about the potential efficacy or nonefficacy of that substance. That is, in addition to demonstrating hypothesized placebo effects associated with positive beliefs about the manipulation, it was demonstrated that subjects who hold negative beliefs about a substance they have ingested might experience a negative placebo (or "nocebo") effect. Clearly, because no pharmacologically or physiologically active substances were administered in the present study, it cannot be stated whether, had they been so, observed physiological or pharmacological effects would have been augmented or diminished by such belief effects. (The degree to which placebo and pharmacological effects might augment one another in a simple additive fashion or to which they might interact in a more complex manner is as yet unknown.) Nonetheless, such an effect would be a logical conclusion to draw from our data, given previous findings.
An interesting feature of the data presented here is the different pattern of response to the manipulation observed between the 2 groups. That is, not only was there a significant difference in delta scores between groups, but also mean experimental times became progressively faster over time in the positive-belief group while becoming progressively slower over time in the negative-belief group. The instructions employed, and the beliefs catalyzed by these instructions, were highly specific to the nature of the performance task; despite the fact that subjects in both groups were informed that team-sport athletes had found the substance to be ergogenic in endurance performance (a strategy employed to maintain the credibility of the study), each group was provided different expectations of its effects on repeat-sprint performance. The subsequent pattern of response in both groups was arguably highly consistent with these expectations; that is, although both groups ran more slowly in successive baseline trials, the negative-belief group-believing that the substance they had ingested would have a negative effect on repeat-sprint performance-ran more slowly still in each successive experimental trial (Trials 5 and 6 were significantly slower than Trials 1 and 2). The positive-belief group, however, ran faster in each successive experimental trial (mean times for Trials 1 and 6 were almost identical but significantly faster than those for Trials 4 and 5). This pattern is consistent with the belief that the ergogenic aid would positively affect repeat-sprint performance. It would have been interesting to observe the effects of the experimental manipulation on endurance performance among the same subjects, perhaps especially in the case of the negative-belief group. That is, hypothetically, and on the basis that their repeat-sprint performances were consistent with the experimental manipulation in relation to repeat-sprint performance, these subjects might have had sufficiently strong beliefs in the hypothesized positive ergogenic effect of the same substance on endurance performance to have elicited a positive placebo effect in endurance trials.
On the basis of the suggestions of Atkinson and Nevill (3) , data suggested that we could be more confident that performance effects observed in the negative-belief group were a direct result of the manipulation than we were of those observed in the positive-belief group. Two factors support this contention. First, a greater number of the performances in the negative-belief group fell outside the limits of agreement for baseline trials than in the positive-belief group (33% and 26% of performances, respectively). Second, in the positive-belief group 46% of performances outside the limits of agreement were in the hypothesized direction (i.e., faster than the upper limit), and in the negative-belief group all performances outside the limits of agreement were in the hypothesized direction (i.e., slower than the lower limit). Closer inspection of these data is also interesting; in the positive-belief group all performances slower than the lower limit of agreement were observed in Trial 4, and over 50% of performances faster than the upper limit were observed in Trial 6. In the negative-belief group, performances beyond individual limits of agreement were similarly weighted toward the final trials, with 84% occurring in Trials 5 and 6. In fact, if a fairly crude but arguably supportable criterion is adopted for individual placebo responsiveness-that of 2 or more performances that fall outside individual limits of agreement in the hypothesized direction-it can be seen that whereas 14% of the positive-belief group could be described as placebo responsive, 33% of the negative-belief group could be so defined.
A number of factors could explain this apparent disparity, including betweengroup differences in placebo responsiveness and ceiling effects on performance in the positive-belief group. It is of course possible that negative belief is simply a more powerful influence on behavior than positive belief, although this is speculation. Given that it is not uncommon to have a large degree of variability in response to nutritional interventions in sports-performance research (16) , however, the consistency of nocebo responses in the negative-belief group provides strong evidence for the hypothesis that negative belief about an intervention might negatively affect performance. Furthermore, given that 95% limits of agreement have been described as an overly stringent criterion (13), the fact that over 30% of the performances in the present study exceeded that criterion in the hypothesized directions allows us a degree of confidence in stating that, at least in those cases, observed effects resulted from the experimental manipulation. Such a statistic is-coincidentally or otherwise-consistent with Beecher's calculation, based on his early work on placebo responsiveness in medicine, that approximately 35% of the population are placebo responsive (4) .
Questionnaire data indicated that only 50% of subjects expected the substance to affect their performance. This is arguably a surprisingly low level and hinted that any individual placebo or nocebo responses might be explained by a priori variation in expectation of effect (coincidentally these 50% were split equally across groups). Even so-perhaps disappointingly, given the preceding discussion regarding placebo responsiveness-analysis of questionnaire responses and performance data indicated that there was no easily interpretable relationship between expectation and performance. Similarly, although some individuals suggested that they felt they had performed in accordance with their belief about the substance, others did not, and many simply were not sure. Given the relatively large number of subjects, in designing the study we decided that post hoc interviews would be too costly to run and deemed questionnaires the most reliable and economic means of assessing the subjects' beliefs and perceptions. On examination of the resultant data, however, we considered that the use of a questionnaire had not been especially illuminating, and in future research with large numbers of subjects a more useful and economic approach might be to interview a purposeful sample.
It is likely that the positive impact of belief on performance reported here will come as little surprise to sports scientists. It is consistent with previous research findings in sport and elsewhere. The observed nocebo effect, however-although consistent with research in medicine (11, 12) -is perhaps more noteworthy and warrants further discussion. Arguably, and in comparison with positive (placebo) effects on performance, such nocebo effects can be easily explained as a simple deficit in motivation or confidence among subjects. The intuitive logic of a process whereby a subject is informed that the substance will have a negative effect, feels demotivated as a result of that information, and performs poorly as a result of that demotivation is clear (the mechanisms might of course be far more complex). Nonetheless, the fact that a nocebo effect might operate via such an apparently simple mechanism should not catch sports scientists off guard when they consider its potential impact on performance
The apparent implication of our findings is that if a negative belief about a treatment exerts a negative impact on subsequent performance, negative beliefs about a legitimate treatment could offset some or all of the potentially beneficial pharmacological or physiological effects of that treatment. Whether this is a factor in the real world is perhaps debatable; rarely in the real world would athletes use a nutritional supplement about which they held an explicit negative belief (there are, however, clear implications for the efficacy of interventions such as sport psychology or physiotherapy, treatments about which athletes might have either low expectations or explicitly negative beliefs). In research settings, however, the story might be somewhat different; that is, whereas in the real world it is unlikely that athletes would choose to use a substance about which they held negative beliefs, in research, subjects might often be administered treatments that they perceived might be of no benefit or about which they held explicitly negative beliefs. Such negative beliefs about an intervention might be catalyzed in a number of ways, from a simple lack of faith in the ergogenic qualities of a substance or in the experimenters to strong but negative beliefs about the substance itself or about potential negative side effects. In a recent study (7), the authors described how 1 subject experienced such strong negative side effects to what he believed was a high dose of caffeine-but which was in fact a placebo-that he had to discontinue his participation in the trial in question. Subsequent interview data from the subject suggested that he had, on the basis of previous experience, expected the high-dose condition to have a negative effect. This report is consistent with data from clinical drug trials suggesting that subjects in the placebo arm might experience negative side effects similar or identical to those experienced by subjects in the experimental arm of the study (9) .
Sport and exercise scientists generally accept the premise that the placebo effect can influence dependent variables, and they use strategies to control for this effect in research. The idea that such effects might be negative, however, is perhaps rarely considered when designing-or interpreting the findings of-placebo-controlled studies. One route to better understanding the mechanisms underlying enhanced or reduced levels of performance resulting from an intervention is to measure true baseline conditions alongside both placebo and experimental conditions (that is, the placebo condition effectively becomes an experimental manipulation, albeit a psychological one). It is recognized that this is an expensive and time-consuming process and thus one that is rarely employed. Nonetheless, it is a process that might shed considerable light on the mechanisms underlying the ergogenic effects of substances commonly used in sport. Another approach is to use either interviews or questionnaires to assess aspects of belief and perception, such as the degree of subjects' expectation of a beneficial effect from the substance in question or their perceptions as to the order in which the treatments had been administered. Interview and questionnaire data do not always provide clear-cut explanations; they do, however, help expose the often wide variability in factors such as expectation and belief that subjects bring to the sports-research domain and that in turn might influence performance.
